We use cookies for a better user experience. Read our Privacy Policy

I Agree

Neuroprotection Market

Neuroprotection Market (Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants; Application - Prevention, Treatment) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Neuroprotection Market: Snapshot

The market for Neuroprotection is expected to grow at steady growth rate during the forecast period largely attributed due to increasing drug development in the pharmaceutical and biotechnology industry along with increasing patient population pool, growing incidences of CNS diseases, increasing awareness, increased demand for more target specific drug treatment for Neurodegenerative diseases along with favorable government regulations. The other factors responsible for the growth the market include increasing healthcare infrastructure, increasing economic stability in developing economies, increasing participation of major market players in in developing economies such as Latin America and Middle East & Africa. The North America region in Neuroprotection market is anticipated to hold major market share along with Europe region during the forecast period. The region are expected to grow moderately in comparison to Asia Pacific region during the forecast period whereas, primarily due to the effect of pricing pressure due to increased competition among leading brands, increase of generic products and growing number of regional players who are able to provide products at much lower prices. However, new product launch and robust pipeline are expected to enter Neuroprotection market, which are likely to increase future growth and demand of the Neuroprotection.

Transparency Market Research estimates that the global Neuroprotection market will increase at a CAGR of 8.2% during the forecast period between 2017 and 2025. Driven by the growing healthcare industry, increasing use of Neuroprotection in cosmetics, government initiatives, and rising ageing population, the market valued at US$ 23,170.6 Mn in 2016 in terms of revenue.

neuroprotection market

Based on product type the Neuroprotection market during 2016, the free radical trapping agents held a prominent share of approximately 36.4% of the global Neuroprotection market share. The segment is expected to expand at an equitable growth during the forecast period as equated to the other product types. The high growth segment in Neuroprotection drug class was the free radical trapping agents (Antioxidants) exhibiting a CAGR of 9.0% during the forecast period. The high growth is due to the increasing use antioxidants for treatment of neurodegenerative diseases such as Alzheimer’s and free radical trapping agents are more efficient in preventing further degradation of neural cells. Increasing demand for more efficient drug, increasing use of herbal extract free radical trapping agents such as cannabidiol, Vitamins E and C, and increasing research and development is expected to drive the market during the forecast period. Companies such as Biogen, Inc. have a robust product portfolio for treatment of neurological disorders such as, in June,2017, The European Commission (EC) has allowed an authorization of marketing to Biogen’s drug SPINRAZA (nusinersen), for treating 5q spinal muscular atrophy (SMA) in the European Union (EU).

Based on Application the Neuroprotection market has been segment into: prevention, and treatment. The treatment application is expected to expand at a higher CAGR during the period 2017-2025, whereas the prevention is expected to grow at a lower rate during the forecast period. Increasing demand for highly efficient drug delivery module is expected to drive the market growth.

According to geography the global Neuroprotection market has been distributed into North America, Europe, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for highest share in the global Neuroprotection market in 2016, closely followed by Europe. Asia Pacific is anticipated to be the fastest growing market nonetheless Latin America region is projected to grow under the influence of North America, Europe, and Asia Pacific region due to lack of awareness in the region, but increasing government initiative to promote pharmaceutical and healthcare industry and increase in healthcare expenditure, are expected to boost the demand for Neuroprotection in this region. The changing demographics and rising per capita income of the middle class in pharmerging economies of the Asia and Latin America region such as India and other countries in rest of APAC region are expected to provide lucrative opportunities for the Neuroprotection market during the forecast period. The Middle East & Africa Neuroprotection market is expected to grow under the influence of increasing geographical presence of major manufacturers in the region through strategic mergers & acquisitions, increase in government initiatives to promote research and development pharmaceutical sector in the region is expected to drive the Neuroprotection market in the region during the forecast period.

Major players in the Neuroprotection market include Daiichi Sankyo Company, Eli Lilly and Company, Allergan plc, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Biogen Inc., and other prominent players. Increasing product launches, geographical expansion in the developing economies, and increase in strategic alliances among regional and global manufactures is anticipated to further boost the neuroprotection market. For Instance, in November 2017, Teva Pharmaceutical received FDA approval for neurological and neuropsychiatry drug – Austedo, for treating Huntington disease and Tardive dyskinesia in the U.S.

Rising Cases of Chronic Illnesses such as Parkinson’s disease to Propel Neuroprotection Market

The market for Neuroprotection is required to develop at consistent development rate during the conjecture time frame generally ascribed because of expanding drug improvement in the drug and biotechnology industry alongside expanding patient populace pool, developing occurrences of CNS illnesses, expanding mindfulness, and expanded interest for more objective explicit medication treatment for Neurodegenerative sicknesses alongside good unofficial laws. Different components answerable for the development the market incorporate expanding medical services framework, expanding financial steadiness in creating economies, expanding cooperation of significant market major parts in creating economies like Latin America and Middle East and Africa.

Expanding interest for more proficient medication, expanding utilization of home grown concentrate free extreme catching specialists, for example, cannabidiol, Vitamins E and C, and expanding innovative work is required to drive the market during the conjecture time frame. Organizations like Biogen, Inc. have a hearty item portfolio for treatment of neurological problems, for example, in June,2017, The European Commission (EC) has permitted an approval of showcasing to Biogen's medication SPINRAZA (nusinersen), for treating 5q spinal strong decay (SMA) in the European Union (EU).

Fast expansion in drug area and expanding patient populace has prompted an expanded interest for neuroprotective medications as they end up being profoundly effective in treatment of neurodegenerative illnesses like Alzheimer's, Parkinson's, Macular Sclerosis, and different infections where neural harm happens. These drivers alongside expanding rates of horrendous cerebrum injury are required to drive the Neuroprotection market in the foreseeable future.

The changing socioeconomics and rising per capita pay of the working class in pharmerging economies of the Asia and Latin America area, for example, India and different nations in rest of APAC district are required to give worthwhile freedoms to the Neuroprotection market during the estimate time frame. The Middle East and Africa Neuroprotection market is required to develop affected by expanding geological presence of significant makers in the area through essential consolidations and acquisitions, expansion in government drives to advance innovative work drug area in the district is relied upon to drive the Neuroprotection market in the locale during the figure time frame.

Neuroprotection Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions and Acronyms Used
     2.2. Research Methodology

3. Executive Summary
     3.1. Global Neuroprotection Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025 
     3.2. Global Neuroprotection Market: Market Snapshot

4. Market Overview
     4.1. Global Neuroprotection Market: Product Overview 
     4.2. Global Neuroprotection Market: Key Industry Developments

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Global Neuroprotection Market Outlook
     5.6. Porters Five Forces
     5.7. Pipeline Analysis
     5.8. Mergers & Acquisition
     5.9. Product mapping

6. Global Neuroprotection Market Analysis, by Product
     6.1. Introduction
     6.2. Key Insights
     6.3. Global Neuroprotection Market Value Share Analysis, by Product
     6.4. Global Neuroprotection Market Value (US$ Mn) Forecast , by Product
            6.4.1. Free Radical Trapping Agents (Antioxidants)
            6.4.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
            6.4.3. Apoptosis Inhibitors
            6.4.4. Anti-inflammatory Agents
            6.4.5. Neurotrophic Factors (NTFs)
            6.4.6. Metal Ion Chelators
            6.4.7. Stimulants
            6.4.8. Others
     6.5. Global Neuroprotection Market Attractiveness, by Product

7. Global Neuroprotection Market, By Application
     7.1.  Global Neuroprotection Market Value Share Analysis, by Application
     7.2. Global Neuroprotection Market Value (US$ Mn) Forecast, by Application
            7.2.1. Prevention
            7.2.2. Treatment
     7.3. Global Neuroprotection Market Attractiveness Analysis, by Application
            7.3.1. Prevention
            7.3.2. Treatment

8. Global Neuroprotection Market Analysis, by Region
     8.1. Global Neuroprotection Market Forecast, by Region, 2015–2025 
            8.1.1. North America
            8.1.2. Europe
            8.1.3. Asia Pacific
            8.1.4. Latin America
            8.1.5. Middle East & Africa
     8.2. Global Neuroprotection Market Value Share Analysis, by Region
     8.3. Global Neuroprotection Market Attractiveness Analysis, by Region

9. North America Neuroprotection Market Analysis
     9.1. North America Neuroprotection Market Key Findings
     9.2. North America Neuroprotection Market Overview
     9.3. North America Neuroprotection Market Value Share Analysis, by Product
            9.3.1. Free Radical Trapping Agents (Antioxidants)
            9.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
            9.3.3. Apoptosis Inhibitors
            9.3.4. Anti-inflammatory Agents
            9.3.5. Neurotrophic Factors (NTFs)
            9.3.6. Metal Ion Chelators
            9.3.7. Stimulants
            9.3.8. Others
     9.4. North America Neuroprotection Market Value Share Analysis, by Application
            9.4.1. Prevention
            9.4.2. Treatment
     9.5. North America Neuroprotection Market Forecast, by Country
            9.5.1. U.S.
            9.5.2. Canada
     9.6. North America Neuroprotection Market Attractiveness Analysis
            9.6.1. By Product
            9.6.2. By Application
            9.6.3. By Country
     9.7. Trends

10. Europe Neuroprotection Market Analysis
     10.1. Europe Neuroprotection Market Key Findings
     10.2. Europe Neuroprotection Market Overview
     10.3. Europe Neuroprotection Market Value Share Analysis, by Product
            10.3.1. Free Radical Trapping Agents (Antioxidants)
            10.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
            10.3.3. Apoptosis Inhibitors
            10.3.4. Anti-inflammatory Agents
            10.3.5. Neurotrophic Factors (NTFs)
            10.3.6. Metal Ion Chelators
            10.3.7. Stimulants
            10.3.8. Others
     10.4. Europe Neuroprotection Market Value Share Analysis, by Application
            10.4.1. Prevention
            10.4.2. Treatment
     10.5. Europe Neuroprotection Market Forecast, by Country
            10.5.1. Germany
            10.5.2. U.K.
            10.5.3. France
            10.5.4. Italy
            10.5.5. Spain
            10.5.6. Russia
            10.5.7. Rest of Europe
     10.6. Europe Neuroprotection Market Attractiveness Analysis
            10.6.1. By Product
            10.6.2. By Application
            10.6.3. By Country
     10.7. Trends

11. Asia Pacific Neuroprotection Market Analysis
     11.1. Asia Pacific Neuroprotection Market Key Findings
     11.2. Asia Pacific Neuroprotection Market Overview
     11.3. Asia Pacific Neuroprotection Market Value Share Analysis, by Product
            11.3.1. Free Radical Trapping Agents (Antioxidants)
            11.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
            11.3.3. Apoptosis Inhibitors
            11.3.4. Anti-inflammatory Agents
            11.3.5. Neurotrophic Factors (NTFs)
            11.3.6. Metal Ion Chelators
            11.3.7. Stimulants
            11.3.8. Others
     11.4. Asia Pacific Neuroprotection Market Value Share Analysis, by Application
            11.4.1. Prevention
            11.4.2. Treatment
     11.5. Asia Pacific Neuroprotection Market Forecast, by Country
            11.5.1. China 
            11.5.2. India
            11.5.3. Japan
            11.5.4. Australia & New Zealand
     11.6. Asia Pacific Neuroprotection Market Attractiveness Analysis
            11.6.1. By Product
            11.6.2. By Application
            11.6.3. By Country
     11.7. Trends

12. Latin America Neuroprotection Market Analysis
     12.1. Latin America Neuroprotection Market Key Findings
     12.2. Latin America Neuroprotection Market Overview
     12.3. Latin America Neuroprotection Market Value Share Analysis, by Product
            12.3.1. Free Radical Trapping Agents (Antioxidants)
            12.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
            12.3.3. Apoptosis Inhibitors
            12.3.4. Anti-inflammatory Agents
            12.3.5. Neurotrophic Factors (NTFs)
            12.3.6. Metal Ion Chelators
            12.3.7. Stimulants
            12.3.8. Others
     12.4. Latin America Neuroprotection Market Value Share Analysis, by Application
            12.4.1. Prevention
            12.4.2. Treatment
     12.5. Latin America Neuroprotection Market Forecast, by Country
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of LATAM
     12.6. Latin America Neuroprotection Market Attractiveness Analysis
            12.6.1. By Product
            12.6.2. By Application
            12.6.3. By Country
     12.7. Trends

13. MEA Neuroprotection Market Analysis
     13.1. MEA Neuroprotection Market Key Findings
     13.2. MEA Neuroprotection Market Overview
     13.3. MEA Neuroprotection Market Value Share Analysis, by Product
            13.3.1. Free Radical Trapping Agents (Antioxidants)
            13.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
            13.3.3. Apoptosis Inhibitors
            13.3.4. Anti-inflammatory Agents
            13.3.5. Neurotrophic Factors (NTFs)
            13.3.6. Metal Ion Chelators
            13.3.7. Stimulants
            13.3.8. Others
     13.4. MEA Neuroprotection Market Value Share Analysis, by Application
            13.4.1. Prevention
            13.4.2. Treatment
     13.5. MEA Neuroprotection Market Forecast, by Country
            13.5.1. GCC Countries
            13.5.2. South Africa
            13.5.3. Israel
            13.5.4. Rest of MEA
     13.6. North America Neuroprotection Market Attractiveness Analysis
            13.6.1. By Product
            13.6.2. By Application
            13.6.3. By Country
     13.7. Trends

14. Competition Landscape
     14.1. Global Neuroprotection Market Share Analysis, by Company (2016)
     14.2. Company Profiles
            14.2.1. Daiichi Sankyo Company  
                      14.2.1.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.1.2. Financials
                      14.2.1.3. Recent Developments
                      14.2.1.4. Strategy
            14.2.2. Eli Lilly and Company  
                      14.2.2.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.2.2. Financials
                      14.2.2.3. Recent Developments
                      14.2.2.4. Strategy
            14.2.3. Allergan plc.
                      14.2.3.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.3.2. Financials
                      14.2.3.3. Recent Developments
                      14.2.3.4. Strategy
            14.2.4. Dr. Reddy’s Laboratories Ltd.
                      14.2.4.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.4.2. Financials
                      14.2.4.3. Recent Developments
                      14.2.4.4. Strategy
            14.2.5. Teva Pharmaceutical Industries Ltd. 
                      14.2.5.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.5.2. Financials
                      14.2.5.3. Recent Developments
                      14.2.5.4. Strategy
            14.2.6. Novartis AG  
                      14.2.6.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.6.2. Financials
                      14.2.6.3. Recent Developments
                      14.2.6.4. Strategy
            14.2.7. AstraZeneca plc.
                      14.2.7.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.7.2. Financials
                      14.2.7.3. Recent Developments
                      14.2.7.4. Strategy
            14.2.8. AstraZeneca plc.
                      14.2.8.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.8.2. Financials
                      14.2.8.3. Recent Developments
                      14.2.8.4. Strategy
            14.2.9. Astrocyte Pharmaceuticals, Inc.
                      14.2.9.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.9.2. Financials
                      14.2.9.3. Recent Developments
                      14.2.9.4. Strategy
            14.2.10. F. Hoffmann-La Roche AG
                      14.2.10.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.10.2. Financials
                      14.2.10.3. Recent Developments
                      14.2.10.4. Strategy
            14.2.11. Biogen Inc.
                      14.2.11.1. Overview (HQ, Employee Strength, Business Segments)
                      14.2.11.2. Financials
                      14.2.11.3. Recent Developments
                      14.2.11.4. Strategy

List of Tables

Table 01: Neuroprotection Market: Pipeline Analysis
Table 02: Neuroprotection Market: Pipeline Analysis
Table 03: Neuroprotection Market: Pipeline Analysis
Table 04: Neuroprotection Market Product mapping
Table 05: Neuroprotection Market Product mapping
Table 06: Neuroprotection Market Mergers & Acquisitions
Table 07: Global Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 08: Global Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 09: Global Neuroprotection Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 11: North America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 12: North America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 13: Europe Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 14: Europe Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 15: Europe Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 16: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 17: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 18: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 19: Latin America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 20: Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 21: Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 22: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 23: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 24: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025

List of Figures
           
Figure 01: Global Neuroprotection Market Revenue Projections (US$ Mn), 2015–2025
Figure 02: Global Neuroprotection Market Value Share Analysis, Product, 2016 and 2025
Figure 03: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Free Radical Trapping Agents (Antioxidants), 2015-2025
Figure 04: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Glutamate Antagonists, 2015-2025
Figure 05: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Apoptosis Inhibitors, 2015-2025
Figure 06: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Anti-inflammatory Agents, 2015-2025
Figure 07: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Neurotrophic Factors (NTFs), 2015-2025
Figure 08: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Metal Ion Chelators, 2015-2025
Figure 09: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Stimulants, 2015-2025
Figure 10: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2015-2025
Figure 11: Global Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 12: Global Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 13: Global Neuroprotection Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Prevention, 2015–2025
Figure 14: Global Neuroprotection Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Treatment, 2015–2025
Figure 15: Global Neuroprotection Market Attractiveness Analysis, by Application, 2017–2025
Figure 16: Global Neuroprotection Market Value Share Analysis, by Region, 2016 and 2025
Figure 17: Global Neuroprotection Market Attractiveness Analysis, by Region, 2017–2025
Figure 18: North America Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 19: North America Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
Figure 20: North America Neuroprotection Market Attractiveness Analysis, by Country
Figure 21: North America Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
Figure 22: North America Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
Figure 23: North America Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 24: North America Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 25: North America Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
Figure 26: Europe Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 27: Europe Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
Figure 28: Europe Neuroprotection Market Attractiveness Analysis, by Country
Figure 29: Europe Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
Figure 30: Europe Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
Figure 31: Europe Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 32: Europe Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 33: Europe Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
Figure 34: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 35: Asia Pacific Neuroprotection Market Y-o-Y Growth Projection, 2016–2025
Figure 36: Asia Pacific Neuroprotection Market Attractiveness, by Country/Sub-region
Figure 37: Asia Pacific Neuroprotection Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 38: Asia Pacific Neuroprotection Market Value Share, by Product, 2016 and 2025
Figure 39: Asia Pacific Neuroprotection Market Attractiveness, by Product, 2017–2025
Figure 40: Asia Pacific Neuroprotection Market Value Share, by Application, 2016 and 2025
Figure 41: Asia Pacific Neuroprotection Market Attractiveness, by Application, 2017–2025
Figure 42: Latin America Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 43: Latin America Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
Figure 44: Latin America Neuroprotection Market Attractiveness Analysis, by Country
Figure 45: Latin America Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
Figure 46: Latin America Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
Figure 47: Latin America Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 48: Latin America Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 49: Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
Figure 50: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 51: Middle East & Africa Neuroprotection Market Y-o-Y Growth Projection, 2016–2025
Figure 52: Middle East & Africa Neuroprotection Market Attractiveness, by Country/Sub-region
Figure 53: Middle East & Africa Neuroprotection Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 54: Middle East & Africa Neuroprotection Market Value Share, by Product, 2016 and 2025
Figure 55: Middle East & Africa Neuroprotection Market Attractiveness, by Product, 2017–2025
Figure 56: Middle East & Africa Neuroprotection Market Value Share, by Application, 2016 and 2025
Figure 57: Middle East & Africa Neuroprotection Market Attractiveness, by Application, 2017–2025
Figure 58: Global Neuroprotection Market, Company Share, 2016
Figure 59: DAIICHI SANKYO COMPANY, LIMITED R&D Intensity (%) 2015–2016
Figure 60: DAIICHI SANKYO COMPANY, LIMITED Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 61: DAIICHI SANKYO COMPANY, LIMITED Breakdown of Net Sales, By Region, 2016
Figure 62: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 63: Eli Lilly and Company R&D Intensity and Sales – Company Level, 2015–2016
Figure 64: Eli Lilly and Company Breakdown of Net Sales, By Region, 2016
Figure 65: Eli Lilly and Company Breakdown of Net Sales, by Neuroscience products sales, 2016
Figure 66: Allergan plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 67: Allergan plc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 68: Allergan plc. Breakdown of Net Sales, by Business Segment, 2016
Figure 69: Allergan plc. Breakdown of Net Sales, by Central Nervous Products Sale, 2016
Figure 70: Dr. Reddy’s Laboratories Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 71: Dr. Reddy’s Laboratories Ltd. R&D Intensity and Sales & Marketing Intensity US$ Mn – Company Level or Segment Level, 2016–2017
Figure 72: Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales, by Region, 2017
Figure 73: Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales, by Business Segments, 2017
Figure 74: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 75: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 76: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
Figure 77: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016
Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 79: Novartis AG Marketing & Sales, and R&D Expenses, 2015–2016
Figure 80: Novartis AG Breakdown of Net Sales, by Business Segment, 2016
Figure 81: Novartis AG Breakdown of Net Sales, by Region, 2016
Figure 82: AstraZeneca plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 83: Astra Zeneca R&D Intensity (%) 2015–2016
Figure 84: AstraZeneca plc. Breakdown of Net Sales, by Region (Company Level), 2016
Figure 85: AstraZeneca plc. Breakdown of Net Sales, by Therapy areas 2016
Figure 86: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 87: F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
Figure 88: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
Figure 89: F. Hoffmann-La Roche AG Breakdown of Net Sales (Pharmaceutical Segment), by Region,  2016
Figure 90: Biogen Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 91: Biogen R&D Intensity (%), 2015–2016
Figure 92: Biogen Breakdown of Net Sales, by Region, 2016
Figure 93: Biogen Breakdown of Net Sales, by Product, 2016

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

715

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved